COVID-19 Rapid Clinical Updates: The Present and Future State of COVID-19 Management

Beginning with the hospital and expanding our focus to all healthcare settings, we examine current therapies for COVID-19 pandemic alongside emerging therapies for COVID-19 as an endemic. Panelists will touch on future oral therapies in the context of readmissions, post discharge, long haulers, and mutations while fielding audience questions.


Jagriti Chadha, MD, FHM


Schmuel Shoham, MD


This activity was made possible in part by an educational grant from Gilead Sciences, Inc.


Target Audience

This activity is designed for hospitalists and front line clinicians working working with COVID-19 patients.

Learning Objectives

  • Evaluate current guidance for treatment of COVID-19 patients requiring hospitalization
  • Review COVID-19 hospitalization trends in the US
  • Discuss findings from randomized clinical trials for treatments in hospitalized COVID-19 patients
  • Understand recent recommendations regarding the diagnosis and prevention of VTE in hospitalized adult COVID-19 patients
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician
Course opens: 
Course expires: 
Your cost:

Shmuel Shoham, MD

  • Research support payments from DoD, NIH, Bloomberg Foundation, Ansun, Cidara, F2G

  • Direct payment from Intermountain Health, Celltrion, Adagio, Immunome, Karyopharm for DSMB and advisory board membership

Remaining faculty had no relevant financial or advisory relationships with corporate organizations related to this activity.


In accordance with the ACCME Standards for Commercial Support, SHM requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. SHM resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. All relevant financial relationships shall be disclosed to participants prior to the start of the activity.

Furthermore, SHM seeks to verify that all scientific research referred to, reported, or used in a continuing medical education (CME) activity conforms to the generally accepted standards of experimental design, data collection, and analysis. SHM is committed to providing its learners with high-quality CME activities that promote improvements in healthcare and not those of a commercial interest.

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.

The Society of Hospital Medicine designates this live activity, for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity

The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provider continuing medical education for physicians.

SHM is dedicated to promoting the highest quality care for all hospitalized patients. SHM is committed to promoting excellence in the practice of hospital medicine through education, advocacy and research.

This activity was made possible in part by an educational grant from Gilead Sciences, Inc.


Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-physician


Your cost:
Please login or register to take this course.

Click the START button to enter the meeting evaluation.